Abstract
Faster time to action and facilitated review are the expected benefits when regulatory agencies use computer-assisted new drug applications (CANDAs). Although no statistics are available to support these benefits, CANDAs continue to be used widely. Sponsors began to use CANDAs in-house also, and the benefits in this area were unexpected. This research of 32 pharmaceutical sponsors showed that when CANDAs were used internally, a better quality new drug application (NDA) appears to result. Use of CANDAs by sponsors in preparing an NDA did not extend the time of submission preparation; nor did it appear to speed the process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
